Evidence map›Paper›PMID 31542863›Full record

ArticleJournal of neuro-oncology2019

Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.

Daniel I Hoffman, Kalil G Abdullah, Makayla McCoskey, Zev A Binder, Donald M O'Rourke, Arati S Desai, MacLean P Nasrallah, Ashkan Bigdeli, Jennifer J D Morrissette, Steven Brem and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Daniel I HoffmanPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Kalil G AbdullahDepartment of Neurosurgery, University of Pennsylvania, Philadelphia, PA, USA.
Makayla McCoskeyPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Zev A BinderDepartment of Neurosurgery, University of Pennsylvania, Philadelphia, PA, USA.
Donald M O'RourkeDepartment of Neurosurgery, University of Pennsylvania, Philadelphia, PA, USA.
Arati S DesaiDivision of Hematology and Oncology, Department of Medicine, University of Pennsylvania, 10th Floor, South Pavilion, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA.
MacLean P NasrallahDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Ashkan BigdeliDepartment of Pathology and Laboratory Medicine, Center for Personalized Diagnostics, University of Pennsylvania, Philadelphia, PA, USA.
Jennifer J D MorrissetteDepartment of Pathology and Laboratory Medicine, Center for Personalized Diagnostics, University of Pennsylvania, Philadelphia, PA, USA.
Steven BremDepartment of Neurosurgery, University of Pennsylvania, Philadelphia, PA, USA.
Stephen J BagleyDivision of Hematology and Oncology, Department of Medicine, University of Pennsylvania, 10th Floor, South Pavilion, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. Stephen.Bagley@uphs.upenn.edu.ORCID http://orcid.org/0000-0002-7117-0539
University of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeYoung adults with isocitrate-dehydrogenase wild-type (IDH-WT) glioblastoma (GBM) represent a rare, understudied population compared to pediatric high-grade glioma, IDH-mutant GBM, or IDH-WT GBM in older patients. We aimed to explore the prognostic impact of epidermal growth factor receptor copy number gain (EGFR CN gain), one of the most common genetic alterations in IDH-WT glioma, in young adults with IDH-WT GBM.

methodsWe performed a retrospective cohort study of patients 18-45 years old with newly diagnosed, IDH-WT GBM whose tumors underwent next-generation sequencing at our institution between 2014 and 2018. The impact of EGFR CN gain on time to tumor progression (TTP) and overall survival (OS) was assessed. A validation cohort of patients 18-45 years old with IDH-WT GBM was analyzed from The Cancer Genome Atlas (TCGA).

resultsTen of 28 patients (36%) from our institution had EGFR CN gain, which was associated with shorter TTP (median 6.5 vs. 11.9 months; p = 0.06) and OS (median 16.3 vs. 23.5 months; p = 0.047). The negative prognostic impact of EGFR CN gain on OS persisted in a multivariate model (HR 6.40, 95% CI 1.3-31.0, p = 0.02). In the TCGA cohort (N = 43), EGFR CN gain was associated with shorter TTP and worse OS, although these did not reach statistical significance (TTP, median 11.5 vs. 14.4 months, p = 0.18; OS, median 23.6 vs. 27.8 months; p = 0.18).

conclusionsEGFR CN gain may be associated with inferior outcomes in young adults with newly diagnosed, IDH-WT GBM, suggesting a potential role for targeting EGFR in this population.

Indexed as

AdolescentAdultBrain NeoplasmsDNA Copy Number VariationsErbB ReceptorsFemaleGlioblastomaHumansIsocitrate DehydrogenaseKaplan-Meier EstimateMaleMiddle AgedPrognosisRetrospective StudiesYoung AdultErbB ReceptorsIsocitrate DehydrogenaseEpidermal growth factor receptorGlioblastomaisocitrate dehydrogenaseNext generation sequencingSurvival

Identifiers

PMID31542863
OpenAlexW2973892140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.